Assurance labs are back
On Monday, the Utah Department of Commerce will announce a roster of AI validation and oversight companies that can vet and oversee participants in its AI sandbox, according to two people with knowledge of the announcement.
Back in July, I reported that Utah was looking into the role independent third parties could play in verifying AI health products and providing oversight for its AI sandbox. In August, the state put out a paper that laid out its perspective on what kind of evidence companies in its AI sandbox need to generate to demonstrate both public health utility and safety. The paper also said AI sandbox applicants should include plans for third party validation of their internal findings. Now, the Utah Department of Commerce is hosting an event wherein it will announce several companies that sandbox applicants can engage to vet and monitor their technology—and provide data back to Utah— for the duration of their sandbox pilot.
The independent third parties will in some cases partner with health systems to validate AI technology that's used at the point of care. In the case where a sandbox product is part of a platform like Doctronic, let's say, the third party will monitor, validate, or offer other governance services directly within the platform.
Why it matters: Utah has emerged as one of the country's most important testing grounds for how AI in health care should be regulated. Anyone building technology in this space should be paying attention. The way that it develops its sandbox program has wide repercussions as both other states and federal regulators try to figure out how to oversee health AI products.
Are these assurance labs? Some of you may remember the stir around AI assurance labs that happened around 2024. The Coalition for Health AI, an organization originally comprising representatives from big-name health providers and tech companies including Mayo Clinic, Duke Health, Microsoft, Amazon, and Google, sought to create a framework for validating health AI products. The idea was that assurance labs, independent third-party evaluators, would vet health AI algorithms. It even had support from the Department of Health and Human Services under President Joe Biden.
However, the assurance lab concept fizzled before it even really got started as industry consensus started to coalesce around the idea that AI needed to be vetted locally, inside of the health systems where it was being deployed. Then, under President Donald Trump, HHS publicly rejected CHAI, suggesting that it was a cover for regulatory capture under big tech.
Well, Utah is bringing assurance labs back effectively. I would expect CHAI to make an appearance next week as Utah embraces its new independent third-party AI evaluator program.
— Ruth
And now onto the news…
`
Upcoming Sessions
Live conversations with the people shaping healthcare.
Is It Finally the Moment for Alternative Plan Design?
Employers are under growing pressure to control healthcare costs while improving access, outcomes, and the member experience. That has renewed interest in
Type 2 Diabetes & Cardiometabolic Care: Wearables, AI & GLP-1s
The rise of wearables, GLP-1s, and AI is reshaping treatment for Type 2 diabetes, weight loss, and metabolic disease. We have
Verifying AI in Medicine: Is Healthcare AI Actually Ready for Deployment?
Is AI ready for real-world clinical care? Dr. Zak Kohane and Protege’s Engy Ziedan debate what it takes to safely trust AI in diagnosis and treatment, from benchmark performance and clinical evidence to whether we’re holding AI to a higher standard than humans.
Why Are Hospitals Hiring Chief AI Officers?
As AI moves from pilots into day-to-day healthcare operations, health systems are having to decide who should actually own the
Where are AI Agents Actually Working in Healthcare, and Why?
While the healthcare industry remains locked in a high-level debate over the theoretical potential of artificial intelligence, a select group of
Top Employers Share What Healthcare Startups Need to Know in 2026
As enterprise health purchasers face volatile medical cost trends and tightening operational margins, the standard vendor pitch of "improved clinical efficiency&
Peptide Therapy: Where Do We Go From Here?
Watch the full webinar Peptide therapies have moved from niche biohacking circles into mainstream medicine, reshaping conversations around weight management, metabolic health,
Not everyone can access the top 1% of physicians. Will AI change that?
Historically, top-tier medical expertise was limited by wealth and geography. As AI reshapes healthcare delivery, a vital question emerges: can it democratize intelligence to give everyone access to the caliber of care typically reserved for the top 1%?
Privacy AI and the Future of HIPAA
Watch the Full Webinar As AI reshapes healthcare and more patient data flows beyond traditional clinical settings, the rules governing privacy, access,